playing god?

Season Two of playing god? is coming soon. Here's a preview of what's in the works.

Back in the 1960s, a committee of seven Seattle residents met regularly to decide which patients with chronic kidney disease were “worthy” of life-saving dialysis.  Whoever wasn’t selected by the committee would likely die within months. An exposé of this so-called “God Squad” helped spark the formation of a new field: bioethics. In this prequel to playing god?, we’ll find out how this committee made life-and-death decisions, and why something like it is unlikely to happen again. Show Notes:This episode features interviews with: Richard M. Mizelle, Jr., Associate Professor of History, University of HoustonKate Butler, Assistant Professor of Nephrology, University of Washington School of MedicineThe God Squad was just one of many notable cases that led to the formation of the field of bioethics. The Hastings Center, a bioethics research institute, has compiled a timeline of many of the most famous cases and their impact. Check it out here. The Berman Institute has also collected oral histories– first hand accounts of the doctors, philosophers, lawyers and other scholars who were involved in many of these cases. You can explore that collection here. To learn more about the ethics issues raised in this episode, visit the Berman Institute’s episode guide. The Greenwall Foundation seeks to make bioethics integral to decisions in health care, policy, and research. Learn more at greenwall.org.

In this episode we head into the future to learn about a controversial technology that could change the face of reproduction. Researchers are developing a technology called in vitro gametogenesis (IVG), which can reprogram human cells–like a skin cell–to become eggs or sperm. With IVG we could reach a future where anyone could produce either eggs or sperm, in potentially limitless quantities. This could open up a whole world of new options for how humans reproduce. Startup companies are working to bring this science to the public in ways that bypass the usual research routes for new reproductive technologies. When would it be ethically acceptable to try IVG to make a baby? How can we ensure the technology will be used ethically, including how it should be regulated? Show Notes:This episode features interviews with:Amander Clark, Professor, Molecular, Cell and Developmental Biology,  University of California, Los AngelesI. Glenn Cohen, James A. Attwood and Leslie Williams Professor of Law, Deputy Dean and Faculty Director, Petrie-Flom Center for Health Law Policy, Biotechnology & Bioethics, Harvard Law SchoolIn 2023, the National Academies held a meeting to discuss the scientific, ethical, and legal implications of IVG. You can watch this meeting and learn more about IVG here. To learn more about the ethics issues raised in this episode, visit the Berman Institute’s episode guide. The Greenwall Foundation seeks to make bioethics integral to decisions in health care, policy, and research. Learn more at greenwall.org.

Cheryl Yoder’s son Jase, was born with an incurable rare disease called spinal muscular atrophy (SMA), which meant he was unlikely to live beyond two years old. Jase managed to get a spot in a clinical trial for an experimental drug. It halted the disease and allowed him to grow up as an active little boy–a miracle cure.  A growing list of uniquely tailored drugs can treat, and even cure, some debilitating and fatal diseases. But often these so-called “miracle drugs” can cost a fortune. In this episode: why miracle drugs cost so much, why it’s so hard to do anything about the costs and how challenging it is to work towards equitable access for patients who can benefit from them.Show Notes:In addition to Cheryl Yoder, this episode features interviews with:Tom Crawford, Co-Director, Muscular Dystrophy Association Clinic and Professor of Neurology, Johns Hopkins University School of MedicineHolly Fernandez Lynch, Assistant Professor of Medical Ethics and Health Policy, University of PennsylvaniaYou can learn more about spinal muscular atrophy, learn about the latest research, and find resources for those affected by the disease here. To learn more about the ethics issues raised in this episode, visit the Berman Institute’s episode guide. The Greenwall Foundation seeks to make bioethics integral to decisions in health care, policy, and research. Learn more at greenwall.org.

For years Brandy Ellis had tried everything to treat depression but nothing worked. Then one day she heard about something called deep brain stimulation, a brain implant that treats some neurological conditions. This technological intervention–that changed her life–also raises ethics questions. Because brain implants have the potential to change our personalities and our performance– where do we draw the line? Are we giving such devices too much control over who we are by using them to alter fundamental human traits like our emotions?Note: This episode contains references to suicide.  If you or someone you know is struggling with thoughts of suicide, there are resources that can help you. In the US, dial 988 to reach the Suicide & Crisis lifeline for free 24/7 confidential support from a trained listener. Or text SAVE to 741741 to reach a trained helper at the Crisis Text Line.Show Notes:In addition to Brandy Ellis, this episode features interviews with: Patricio Riva Posse, Associate Professor, Psychiatry and Behavioral Sciences, Emory University School of MedicineKaren Rommelfanger, Founding Director, Institute of Neuroethics; CEO, Ningen Neuroethics Co-Lab;  Senior Faculty Fellow, Emory University Center for Ethics (previously director of the Neuroethics Program); Adjunct Associate Professor,  Departments of Neurology, Psychiatry & Behavioral Sciences, Emory University School of Medicine.You can learn more about deep brain stimulation (DBS) here.To learn more about the ethics issues raised in this episode, visit the Berman Institute’s episode guide.  The Greenwall Foundation seeks to make bioethics integral to decisions in health care, policy, and research. Learn more at greenwall.org.